Analysis and Evaluation of Smoking Treatment With Cytisine: Retrospective Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- Therapeutic adherence
研究概览
简要总结
The lack of clinical studies on the use of Cytisine in the treatment of the cessation of smoking, the need to find effective therapeutic alternatives and the opportunity to reduce costs related to the complications of cigarette smoking, represent the main reasons that led to the design of this study.
详细描述
The study is observational, retrospective and monocentric, and aims to evaluate patients who performed an initial pneumological examination at the Anti-Smoking Center of the National Institute Regina Elena tumors due to smoking cessation in the reference period. To such patients, affected of moderate or severe tobacco use disorder, drug therapy was prescribed with Cytisine 1.5 mg, with the aim of evaluating treatment adherence, efficacy and tolerability of Cytisine as monotherapy in the treatment of moderate or moderate tobacco use disorder serious. Responding patients will be taken into consideration for the study consecutively to the criteria established and pertaining to the Anti-Smoking Center of the National Cancer Institute Regina Elena in the period between 02/01/2023 and 11/30/2023 on first and subsequent visits controls.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients aged > 18 years;
- •patients suffering from moderate or severe tobacco use disorder;
- •prescription of pharmacological therapy with Cytisine;
- •patients returned to the 1st check-up on schedule;
排除标准
- •Patients with contraindications to taking Cytisine and partial receptor agonists nicotinic cholinergics;
- •Patients undergoing pharmacological or physical treatment for neoplastic pathology;
- •Pregnant or breastfeeding women;
- •Patients for whom specific information for objective assessments is not available;
研究组 & 干预措施
Patients with moderate or severe tobacco use disorder.
Patients hospitalized at the IRE anti-smoking center, National Cancer Institute "Regina Elena", suffering from moderate or severe tobacco use disorder, who are prescribed pharmacological therapy with Cytisine 1.5 mg.
干预措施: Cytisine 1,5 mg (Drug)
结局指标
主要结局
Therapeutic adherence
时间窗: 3 months
Evaluation of adherence to the prescribed drug therapy i.e. Cytisine 1.5 mg
次要结局
- Evaluation of the effectiveness of the therapy.(3 months)
- Evaluation of therapeutic adherence in relation to motivation.(3 months)
- Safety and Tolerability assessment.(3 months)
- Assessment of adherence in relation to the dependency score physics.(3 months)